This article examines a recent study by a UVA neuroscientist that reveals how new GLP-1 weight-loss drugs not only suppress appetite but also alter the brain’s reward pathways, raising significant implications for addiction, impulse control, and the overall experience of eating.
A study conducted by researchers at the University of Virginia (UVA) has uncovered significant insights into the neurological effects of a new class of weight-loss drugs known as GLP-1 (glucagon-like peptide-1) agonists. Published in the journal Nature, this research highlights how these medications, which were initially developed to treat Type 2 diabetes, may fundamentally alter patients’ relationship with food and their overall experience of eating.
Led by neuroscientist Ali D. Güler, the study aimed to explore not just the appetite-suppressing properties of GLP-1 drugs, but also their influence on brain circuits related to reward and motivation. “These drugs are incredibly effective,” Güler stated. “But what we wanted to understand is what they’re doing in the brain.”
More Than Just an Appetite Suppressant
Originally, GLP-1 drugs were recognized for their ability to improve insulin response in those with diabetes, with weight loss viewed as a beneficial side effect. However, the UVA research team utilized a unique, genetically engineered mouse model to demonstrate that these newer small-molecule GLP-1 drugs can penetrate deep regions of the brain. Previous studies had confirmed their action on neurons within the hindbrain, responsible for regulating basic functions and feelings of fullness. However, Güler’s team discovered that the drugs also activate a neural circuit connecting the hindbrain to the central amygdala, a region involved in emotional processing, and ultimately to dopamine-producing neurons. This pathway plays a crucial role in how the brain assigns value to rewarding experiences, such as consuming high-calorie foods.
“What we show is that these drugs can reduce not just hunger, but the desire to pursue rewarding food,” Güler explained. “They’re acting on the system that makes you want the cake, not just the system that makes you feel full.” These findings also help elucidate variations among different GLP-1 compounds, as some appear to induce more nausea-like effects, while others minimize discomfort while effectively reducing food motivation.
Implications for Industry and Society
The timing of this discovery is noteworthy, as pharmaceutical companies are racing to develop more affordable and accessible alternatives to injectable GLP-1 drugs. Oral formulations present several advantages, including easier production, greater shelf stability, and significantly lower costs. This could potentially open up the market to millions of individuals, with projections suggesting that profits could reach hundreds of billions of dollars in the coming years, according to Güler. However, the research also poses essential questions regarding the broader implications of these drugs. “If these drugs are affecting reward pathways in the brain, that has implications beyond weight loss,” he remarked. “It could influence things like addiction, impulse control, or even how people experience pleasure.”
Preliminary evidence indicates that some patients may find it easier to quit smoking or manage other compulsive behaviors while using GLP-1 drugs. Conversely, others report a diminished enjoyment of food. Güler emphasizes that both aspects warrant further investigation. “As scientists, our job is not just to say that something works,” he noted. “It’s to understand how it works, so we can improve it and anticipate unintended consequences.”
Student-Driven Discovery
This research not only represents a significant scientific advancement but also showcases a major educational accomplishment. The study encompasses what is equivalent to three doctoral dissertations, with three co-first authors each leading major components of the work, from developing the animal model to mapping neural circuits and analyzing behavior. Over a dozen undergraduate students contributed to the project, collaborating closely with graduate researchers who effectively managed “mini-labs” within the broader initiative.
“On the ground, the experiments were designed and executed by the students,” Güler said, emphasizing their critical role in the study’s success. The project spanned roughly five years, reflecting the collaborative culture of UVA’s biology department and neuroscience programs. Co-lead author Isabelle Sajonia, a fourth-year Ph.D. student in biology, shared, “Working on this paper has been one of the most formative experiences of my graduate career.”
Powered by UVA Support
Unlike many large-scale neuroscience studies, this research was not primarily funded by federal grants but rather through internal support at UVA, including funding from the Brain Institute and various university programs. Güler noted that these investments were crucial to the project, stating, “None of this work was directly funded by NIH. These programs gave us the flexibility to take risks, support students, and sustain a long-term project that would have been very difficult to do otherwise.”
Such relatively modest awards facilitated years of experimental work, particularly in a field characterized by high costs and lengthy timelines, allowing graduate students to dedicate substantial time to the project. Sarah Kucenas, associate dean of research for Arts & Sciences, commented on the study’s significance, stating, “This research shows how targeted, early-stage support can have an outsized impact.”
Looking Ahead
Moving forward, Güler and his team aim to deepen their understanding of the natural roles of the brain circuits identified in their research, as well as how various drugs may target these circuits more effectively. “This is just the beginning,” he remarked. “If we understand these pathways, we may be able to design treatments that target specific behaviors — whether that’s overeating, addiction, or something else entirely.” As GLP-1 drugs become more prevalent, experts emphasize that a comprehensive understanding of their neurological effects is vital, not only to enhance their efficacy but also to anticipate their long-term impacts on behavior and well-being.
“This is about knowing what these drugs are really doing,” Güler concluded. “The more we understand, the better we can make them — for patients and for society.”
